US89157D1054 - TALS (XNAS)
Talaris Therapeutics, Inc. Share
20,91 USD
Current Prices from Talaris Therapeutics, Inc.
Exchange | Ticker | Currency | Last Trade | Price | Daily Change | Daily Change % |
---|---|---|---|---|---|---|
NASDAQ |
TRML
|
USD
|
23.12.2024 20:01
|
20,91 USD
| 20,65 USD | 1,26 % |
Rendimiento
Día | Semana | Mes | 3 meses | 6 meses | 1 año | 5 años |
---|---|---|---|---|---|---|
1,26 % | -0,51 % | -9,13 % | -12,82 % | 36,67 % | -11,40 % | -87,13 % |
Perfil de la empresa para Talaris Therapeutics, Inc. Acción
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Datos de la empresa para Talaris Therapeutics, Inc. Acción
Nombre Talaris Therapeutics, Inc.
Empresa Tourmaline Bio, Inc.
Símbolo TALS
Sitio web https://talaristx.com
Mercado principal
NASDAQ
ISIN US89157D1054
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Sandeep C. Kulkarni M.D.
Capitalización de mercado 394 Mio
País Estados Unidos de América
Moneda USD
Empleados 0,1 T
Dirección 27 West 24th Street, 10010 New York
Fecha de OPV 2021-05-07
Dividends from 'Talaris Therapeutics, Inc.'
Ex-Date | Dividend per Share |
---|---|
19.10.2023 | 0,15 USD |
ID Changes
Date | From | To |
---|---|---|
20.10.2023 | TALS | TRML |
Ticker Symbols
Name | Symbol |
---|---|
NASDAQ | TALS |
NASDAQ | TRML |
More Shares
Investors who Talaris Therapeutics, Inc. hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.